Role Of Ormeloxifene In Management Of Symptomatic Uterine Leiomyoma In Reproductive Age Group

ABSTRACT

Introduction: Abnormal uterine bleeding due to leiomyoma is commomn problem in the reproductive age group and was found to be third most common cause of hysterectomies in teaching hospital of India1. The search for ideal drug for medical management of fioid is still on so that we can avoid operative interventions in symptomatic women of reproductive age group. Ormeloxifene is Selective Estrogen Receptor Modulator developed at CDRI, Luckhnow. It has proven to be an important drug in treatment of AUB, but its utility in fioid is yet to be defined. Through this study, we have explored its role in AUB due to leiomyoma. Aim and objective: To assess decrease in menstrual blood loss (MBL) by pictorial blood loss assessment chart to assess increase in hemoglobin level, to assess change in endometrial thickness, to assess change in fioid size in patients of AUB with leiomyoma treated with Ormiloxifene. Materials and Methods: Subjects were given tablet ormeloxifene 60 mg biweekly for 3 months, followed by 60mg weekly for next 3 months. Subjects were assessed after 3 months and 6 months for MBL, endometrial thickness, fioid volume and hemoglobin level. Observation There was statistically significant decrease in MBL, endometrial thickness, (p=0.0334 and p=0.0096) , increase in hemoglobin(p=0.0001) and no change in fioid volume. after 3 months and 6 months respectivelyConclusion: SERM such as ormeloxifene in standard biweekly dosage is effective in providing symptomatic relief in a patient of AUB-L when prescribed for a short period of 6 months